CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jul. 04, 2021	Jun. 28, 2020	Jul. 04, 2021	Jun. 28, 2020
Income Statement [Abstract]
Revenues	[1]	$ 18,977	$ 9,864	$ 33,559	$ 19,947
Costs and expenses:
Cost of sales	[2]	7,049	1,826	11,259	3,766
Selling, informational and administrative expenses	[2]	2,928	2,659	5,712	5,200
Research and development expenses	[2]	2,459	2,078	4,473	3,750
Amortization of intangible assets		931	869	1,802	1,718
Restructuring charges and certain acquisition-related costs		(1)	360	22	414
(Gain) on completion of Consumer Healthcare JV transaction		0	0	0	(6)
Other (income)/deductions––net		(998)	(955)	(2,001)	(764)
Income from continuing operations before provision for taxes on income		6,609	3,026	12,291	5,868
Provision for taxes on income		1,043	422	1,849	782
Income from continuing operations		5,565	2,604	10,443	5,087
Income from discontinued operations––net of tax		24	893	32	1,774
Net income before allocation to noncontrolling interests		5,589	3,497	10,475	6,860
Less: Net income attributable to noncontrolling interests		26	8	35	17
Net income attributable to Pfizer Inc. common shareholders		$ 5,563	$ 3,489	$ 10,440	$ 6,843
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.99	$ 0.47	$ 1.86	$ 0.91
Income from discontinued operations––net of tax (in dollars per share)		0	0.16	0.01	0.32
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		0.99	0.63	1.87	1.23
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		0.98	0.46	1.84	0.90
Income from discontinued operations––net of tax (in dollars per share)		0	0.16	0.01	0.32
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.98	$ 0.62	$ 1.84	$ 1.22
Weighted-average shares––basic		5,598	5,554	5,591	5,550
Weighted-average shares––diluted		5,678	5,619	5,670	5,616

[1] On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See Note 1A. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.

[2] Exclusive of amortization of intangible assets, except as disclosed in Note 9 in this Form 10-Q and Note 1L in our 2020 Form 10-K.